Patents by Inventor Michelle Tabb
Michelle Tabb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240026467Abstract: Disclosed are methods of identifying a methicillin-resistant Staphylococcus aureus (MRSA) in a sample wherein the methods involve detecting a S. aureus-specific nucleic acid sequence, mecA and mecC, in the sample. Kits for determining the presence of MRSA in a sample are also provided.Type: ApplicationFiled: June 12, 2023Publication date: January 25, 2024Applicant: Quest Diagnostics Investments LLCInventors: Lakshmi NAIR, Heather VINCENT, Huong MAI, Michelle TABB, Maurice EXNER
-
Publication number: 20230279513Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: January 13, 2023Publication date: September 7, 2023Applicant: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Patent number: 11674189Abstract: Disclosed are methods of identifying a methicillin-resistant Staphylococcus aureus (MRSA) in a sample wherein the methods involve detecting a S. aureus-specific nucleic acid sequence, mecA and mecC, in the sample. Kits for determining the presence of MRSA in a sample are also provided.Type: GrantFiled: August 19, 2019Date of Patent: June 13, 2023Assignee: Quest Diagnostics Investments LLCInventors: Lakshmi Nair, Heather Vincent, Huong Mai, Michelle Tabb, Maurice Exner
-
Patent number: 11555223Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: GrantFiled: October 5, 2020Date of Patent: January 17, 2023Assignee: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Publication number: 20210095352Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: October 5, 2020Publication date: April 1, 2021Applicant: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Patent number: 10793924Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: GrantFiled: June 2, 2017Date of Patent: October 6, 2020Assignee: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Patent number: 10724111Abstract: Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.Type: GrantFiled: June 10, 2019Date of Patent: July 28, 2020Assignee: Quest Diagnostics Investments LLCInventors: Peter Lee, Lakshmi Nair, Albert Castro, Maria Vestal, Michelle Tabb
-
Patent number: 10697002Abstract: Disclosed are methods for identifying the presence or absence of a target nucleic acid from one or more organisms in a biological sample, said method comprising: (a) spinning the sample at a rotational velocity sufficient to pellet cellular debris and fluorescence inhibitors present within the sample and reduce fluorescence interference or quenching in the sample; and (b) directly amplifying and detecting the target nucleic acid in the sample.Type: GrantFiled: November 24, 2015Date of Patent: June 30, 2020Assignee: Quest Diagnostics Investments IncorporatedInventors: Lucien Jacky, Albert Castro, Peter Lee, Jose Matud, Michelle Tabb
-
Publication number: 20200140929Abstract: Discloses are methods of identifying a methicillin-resistant Staphylococcus aureus (MRSA) in a sample wherein the methods involve detecting a S. aureus-specific nucleic acid sequence, mecA and mecC, in the sample. Kits for determining the presence of MRSA in a sample are also provided.Type: ApplicationFiled: August 19, 2019Publication date: May 7, 2020Applicant: Quest Diagnostics Investments LLCInventors: Lakshmi Nair, Heather Vincent, Huong Mai, Michelle Tabb, Maurice Exner
-
Publication number: 20190382826Abstract: The present disclosure provides methods for determining whether a patient exhibiting pertussis-like symptoms will benefit from treatment, with therapeutic agents that inhibit Bordetella holmesii. These methods are based on detecting Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii in a biological sample by assaying for the presence of the IS481, IS 1001, and hIS1001 target repeat elements, respectively. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: March 23, 2017Publication date: December 19, 2019Applicant: Quest Diagnostics Investments LLCInventors: Jules Chen, Michelle Tabb
-
Publication number: 20190382856Abstract: Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.Type: ApplicationFiled: June 10, 2019Publication date: December 19, 2019Applicant: QUEST DIAGNOSTICS INVESTMENTS LLCInventors: Peter LEE, Lakshmi Nair, Albert Castro, Maria Vestal, Michelle Tabb
-
Patent number: 10407739Abstract: Disclosed are methods of identifying a methicillin-resistant Staphylococcus aureus (MRSA) in a sample wherein the methods involve detecting a S. aureus-specific nucleic acid sequence, mecA and mecC, in the sample. Kits for determining the presence of MRSA in a sample are also provided.Type: GrantFiled: September 19, 2014Date of Patent: September 10, 2019Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Lakshmi Nair, Heather Vincent, Huong Mai, Michael Aye, Michelle Tabb, Maurice Exner
-
Patent number: 10385408Abstract: Disclosed are methods of identifying a methicillin-resistant Staphylococcus aureus (MRSA) in a sample wherein the methods involve detecting a S. aureus-specific nucleic acid sequence, mecA and mecC, in the sample. Kits for determining the presence of MRSA in a sample are also provided.Type: GrantFiled: September 22, 2014Date of Patent: August 20, 2019Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Lakshmi Nair, Heather Vincent, Huong Mai, Michelle Tabb, Maurice Exner
-
Publication number: 20190211408Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: June 2, 2017Publication date: July 11, 2019Applicant: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Patent number: 10316372Abstract: Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.Type: GrantFiled: September 7, 2018Date of Patent: June 11, 2019Assignee: QUEST DIAGNOSTICS INVESTMENTS LLCInventors: Peter Lee, Lakshmi Nair, Albert Castro, Maria Vestal, Michelle Tabb
-
Publication number: 20190062850Abstract: Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.Type: ApplicationFiled: September 7, 2018Publication date: February 28, 2019Applicant: QUEST DIAGNOSTICS INVESTMENTS LLCInventors: Peter Lee, Lakshmi Nair, Albert Castro, Maria Vestal, Michelle Tabb
-
Patent number: 10072308Abstract: Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.Type: GrantFiled: April 28, 2015Date of Patent: September 11, 2018Assignee: Quest Diagnostics Investments IncorporatedInventors: Peter Lee, Lakshmi Nair, Albert Castro, Maria Vestal, Michelle Tabb
-
Publication number: 20170268043Abstract: Disclosed are methods for identifying the presence or absence of a target nucleic acid from one or more organisms in a biological sample, said method comprising: (a) spinning the sample at a rotational velocity sufficient to pellet cellular debris and fluorescence inhibitors present within the sample and reduce fluorescence interference or quenching in the sample; and (b) directly amplifying and detecting the target nucleic acid in the sample.Type: ApplicationFiled: November 24, 2015Publication date: September 21, 2017Applicant: Quest Diagnostics Inverstments IncorporatedInventors: Lucien Jacky, Albert Castro, Peter Lee, Jose Matud, Michelle Tabb
-
Patent number: 9725762Abstract: Systems and methods for processing sample processing devices. The system can include a sample processing device comprising a detection chamber, a motor configured to rotate the sample processing device about an axis of rotation, and an optical module operatively positioned relative to the sample processing device and configured to determine whether a selected volume of material is present in the detection chamber of the sample processing device. The method can include rotating the sample processing device about an axis of rotation, and determining whether a selected volume of material is present in the detection chamber, while rotating the sample processing device. In some embodiments, determining whether a selected volume of material is present can be performed by optically interrogating the detection chamber for an optical property of the material.Type: GrantFiled: October 13, 2015Date of Patent: August 8, 2017Assignee: Diasorin S.P.A.Inventors: Peter D. Ludowise, David A. Whitman, Kyle C. Armantrout, Maurice Exner, Lucien A. E. Jacky, Michelle Tabb
-
Publication number: 20170051364Abstract: Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.Type: ApplicationFiled: April 28, 2015Publication date: February 23, 2017Applicant: QUEST DEAGNOSTICS INCESTMENTS INCORPORATEDInventors: Peter Lee, Lakshmi Nair, Albert Casto, Maria Vestal, Michelle Tabb